Matches in SemOpenAlex for { <https://semopenalex.org/work/W4353071194> ?p ?o ?g. }
- W4353071194 endingPage "619" @default.
- W4353071194 startingPage "603" @default.
- W4353071194 abstract "Abstract: The ability to address the cell cycle in cancer therapy brings up new medication development possibilities. Cyclin-dependent kinases are a group of proteins that control the progression of the cell cycle. The CDK/cyclin complexes are activated when specific CDK sites are phosphorylated. Because of their non-selectivity and severe toxicity, most first-generation CDK inhibitors (also known as pan-CDK inhibitors) have not been authorized for clinical usage. Despite this, significant progress has been made in allowing pan-CDK inhibitors to be employed in clinical settings. Pan-CDK inhibitors' toxicity and side effects have been lowered in recent years because of the introduction of combination therapy techniques. As a result of this, pan-CDK inhibitors have regained a lot of clinical potential as a combination therapy approach. The CDK family members have been introduced in this overview, and their important roles in cell cycle control have been discussed. Then, we have described the current state of CDK inhibitor research, with a focus on inhibitors other than CDK4/6. We have mentioned first-generation pan-CDKIs, flavopiridol and roscovitine, as well as second-generation CDKIs, dinaciclib, P276-00, AT7519, TG02, roniciclib, and RGB-286638, based on their research phases, clinical trials, and cancer targeting. CDKIs are CDK4/6, CDK7, CDK9, and CDK12 inhibitors. Finally, we have looked into the efficacy of CDK inhibitors and PD1/PDL1 antibodies when used together, which could lead to the development of a viable cancer treatment strategy" @default.
- W4353071194 created "2023-03-23" @default.
- W4353071194 creator A5002626922 @default.
- W4353071194 creator A5018064188 @default.
- W4353071194 creator A5021805044 @default.
- W4353071194 creator A5065814410 @default.
- W4353071194 date "2023-09-01" @default.
- W4353071194 modified "2023-09-27" @default.
- W4353071194 title "An Overview of CDK Enzyme Inhibitors in Cancer Therapy" @default.
- W4353071194 cites W1527674890 @default.
- W4353071194 cites W1646788158 @default.
- W4353071194 cites W185031056 @default.
- W4353071194 cites W1859306058 @default.
- W4353071194 cites W1969317010 @default.
- W4353071194 cites W1975186639 @default.
- W4353071194 cites W1983474840 @default.
- W4353071194 cites W1991601194 @default.
- W4353071194 cites W1993682056 @default.
- W4353071194 cites W1995038735 @default.
- W4353071194 cites W1996138445 @default.
- W4353071194 cites W1997551404 @default.
- W4353071194 cites W2001570690 @default.
- W4353071194 cites W2012363216 @default.
- W4353071194 cites W2020323633 @default.
- W4353071194 cites W2026004604 @default.
- W4353071194 cites W2030742860 @default.
- W4353071194 cites W2031907351 @default.
- W4353071194 cites W2036690838 @default.
- W4353071194 cites W2039782788 @default.
- W4353071194 cites W2042563409 @default.
- W4353071194 cites W2056334059 @default.
- W4353071194 cites W2057272791 @default.
- W4353071194 cites W2058314877 @default.
- W4353071194 cites W2059374495 @default.
- W4353071194 cites W2060508679 @default.
- W4353071194 cites W2062120857 @default.
- W4353071194 cites W2065392523 @default.
- W4353071194 cites W2066812263 @default.
- W4353071194 cites W2069282766 @default.
- W4353071194 cites W2073275756 @default.
- W4353071194 cites W2075152619 @default.
- W4353071194 cites W2078619764 @default.
- W4353071194 cites W2080443370 @default.
- W4353071194 cites W2081279948 @default.
- W4353071194 cites W2084810833 @default.
- W4353071194 cites W2085387015 @default.
- W4353071194 cites W2085553407 @default.
- W4353071194 cites W2089353165 @default.
- W4353071194 cites W2096099528 @default.
- W4353071194 cites W2097906665 @default.
- W4353071194 cites W2097981550 @default.
- W4353071194 cites W2105172500 @default.
- W4353071194 cites W2106480783 @default.
- W4353071194 cites W2108383220 @default.
- W4353071194 cites W2109123712 @default.
- W4353071194 cites W2116922891 @default.
- W4353071194 cites W2131017274 @default.
- W4353071194 cites W2135129680 @default.
- W4353071194 cites W2139793858 @default.
- W4353071194 cites W2140277695 @default.
- W4353071194 cites W2143238584 @default.
- W4353071194 cites W2149469110 @default.
- W4353071194 cites W2149765709 @default.
- W4353071194 cites W2154626333 @default.
- W4353071194 cites W2155347351 @default.
- W4353071194 cites W2155762742 @default.
- W4353071194 cites W2170846478 @default.
- W4353071194 cites W2171613528 @default.
- W4353071194 cites W2176436801 @default.
- W4353071194 cites W2188633642 @default.
- W4353071194 cites W2189238890 @default.
- W4353071194 cites W2204380965 @default.
- W4353071194 cites W2282215407 @default.
- W4353071194 cites W2503782024 @default.
- W4353071194 cites W2512442926 @default.
- W4353071194 cites W2534300354 @default.
- W4353071194 cites W2582141458 @default.
- W4353071194 cites W2583136106 @default.
- W4353071194 cites W2598063839 @default.
- W4353071194 cites W2606835938 @default.
- W4353071194 cites W2611326266 @default.
- W4353071194 cites W2738102269 @default.
- W4353071194 cites W2750328162 @default.
- W4353071194 cites W2769376007 @default.
- W4353071194 cites W2772476552 @default.
- W4353071194 cites W2777560921 @default.
- W4353071194 cites W2783507731 @default.
- W4353071194 cites W2789574985 @default.
- W4353071194 cites W2792645148 @default.
- W4353071194 cites W2799372852 @default.
- W4353071194 cites W2799790020 @default.
- W4353071194 cites W2805204190 @default.
- W4353071194 cites W2808021061 @default.
- W4353071194 cites W2808349768 @default.
- W4353071194 cites W2808614376 @default.
- W4353071194 cites W2890675306 @default.
- W4353071194 cites W2900251974 @default.
- W4353071194 cites W2912285514 @default.